Fosifloxuridine Nafalbenamide is a small molecule commercialized by NuCana, with a leading Phase II program in Metastatic Colorectal Cancer. According to Globaldata, it is involved in 4 clinical trials, of which 2 were completed, 1 is ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Fosifloxuridine Nafalbenamide’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Fosifloxuridine Nafalbenamide is expected to reach an annual total of $46 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Fosifloxuridine Nafalbenamide Overview
NuCana Overview
NuCana is a clinical-stage biopharmaceutical company that develops novel and transformational medicines for the treatment of cancer. The company pipeline products include NUC-3373 targets advanced colorectal cancer; NUC-7738 for advanced solid tumors; acelarin (NUC-1031); and NuTide 121 treats metastatic biliary tract cancer, gemcitabine for biliary tract cancer, pancreatic cancer, ovarian cancer, non-small cell lung cancer, bladder and breast cancers. NuCana develops products based on the ProTide technology platform, which focuses on developing new-generation, anti-cancer agents. The company operates in the UK and the US. NuCana is headquartered in Edinburgh, Scotland, the UK.
The operating loss of the company was GBP32.8 million in FY2023, compared to an operating loss of GBP39.1 million in FY2022. The net loss of the company was GBP27.6 million in FY2023, compared to a net loss of GBP32 million in FY2022.
For a complete picture of Fosifloxuridine Nafalbenamide’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
